Charles River Laboratories International Inc. (CRL)
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.06B
- P/E (TTM)
- 341.65
- Forward P/E
- 24.24
- EPS (TTM)
- $0.92
- Dividend yield
- None
- 52-week range
- 146.20 – 379.63
- Day range
- 310.52 – 327.23
- Volume / Avg
- 1.15M / 1.04M
- Beta
- —
- Shares outstanding
- 47.92M
52-week range
CRL stock today
Charles River Laboratories International (CRL) closed at $314.32 on Nov 20, down 4.15% (-$13.61), versus the S&P 500's 3.70% decline. Shares are 17.2% below their 52-week high of $379.63, set on Oct 29, 2026 and 115.0% above the 52-week low of $146.20, in the middle of the past year's range. CRL is up 57.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 87.5%.
At 341.7x trailing earnings, Charles River Laboratories International trades above the peer-group median of 66.6x. Its forward P/E of 24.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Charles River Laboratories International
Company profileCharles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Ms. Birgit Girshick
- Headquarters
- Wilmington, MA
- Employees
- 18,300
- IPO year
- 2000
- Website
- criver.com
Financial highlights
Full financialsIn fiscal 2025, Charles River Laboratories International generated $4.02 billion in revenue, down 0.9% from fiscal 2024, its first annual decline since 2024. Charles River Laboratories International reported a net loss of $144.3 million, compared with net income of $22.2 million a year earlier. Operating margin was 0.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Growth | -0.85% | -1.92% | +3.86% | +12.31% | +21.08% |
| Net income | $-144.34M | $22.20M | $474.62M | $486.23M | $390.98M |
| EPS (diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$350.57+11.53%
- Strong buy 3
- Buy 11
- Hold 2
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $6.86 vs $2.98
- Surprise
- +130.20%
CRL news
All CRL news- Charles River Stock Surges 102.3% in a Year: What's Fueling the Drive?NasdaqCRL, IDXX, PODD, BLCO
- Should You Continue to Hold Charles River Stock in Your Portfolio?NasdaqCRL, ISRG, IDXX, GKOS
- GMRS vs. CRL: Which Stock Should Value Investors Buy Now?NasdaqGMRS, CRL
- Here's Why Charles River Laboratories (CRL) is a Strong Momentum StockNasdaq
- Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK BusinessesNasdaq
- Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and ProspectsNasdaq
- Charles River To Buy Frontage's Bioanalysis And DMPK Operations For Up To $545 Mln CashNasdaq
- Charles River Laboratories International, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
Charles River Laboratories International peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs CRL |
| MEDPMedpace Holdings Inc. | 610.54 | -3.70% | $17.08B | vs CRL |
| INCYIncyte Corp. | 114.63 | -1.07% | $23.36B | vs CRL |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs CRL |
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs CRL |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs CRL |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs CRL |
| ONMDOneMedNet Corp Class A | 4.70 | +4.21% | $29.15M | vs CRL |
Indexes, lists and sector
Index membership
Charles River Laboratories International stock FAQ
What is Charles River Laboratories International's stock price today?
CRL last traded at $314.32 as of Nov 20, 4:00 PM EST, down 4.15% on the day. Prices are delayed at least 15 minutes.
What is CRL's P/E ratio?
CRL trades at a trailing P/E ratio of 341.65 and a forward P/E of 24.24, compared with a median of 66.6 for its closest peers.
Is Charles River Laboratories International in the S&P 500?
Yes. Charles River Laboratories International (CRL) is a constituent of the S&P 500 index.
Who is Charles River Laboratories International's CEO?
Ms. Birgit Girshick is the chief executive officer of Charles River Laboratories International Inc., which has about 18,300 employees.
What is the CRL 52-week high?
The 52-week high for CRL is $379.63 and the 52-week low is $146.20. The stock is currently 17.2% below its high.